Neurimmune announces additional collaboration with Biogen on human-derived antibodies for neurodegenerative diseases

In 2016, Neurimmune entered into an additional collaboration with Biogen focused on the discovery and validation of human-derived antibodies for the treatment of amyotrophic lateral sclerosis (ALS) and familial frontotemporal dementia (FTD). Under the agreement, the parties conduct joint research to generate and validate antibodies against targets related to hexanucleotide repeat expansion in the C9orf72 gene which is the most common known genetic cause of both ALS and FTD. “We are pleased to expand our successful long-term collaboration with Biogen on Neurimmune’s human therapeutic antibodies and to work jointly on novel targets linked to both ALS and FTD”, said Jan Grimm, Managing Director and Chief Scientific Officer of Neurimmune.